17
Participants
Start Date
April 7, 2023
Primary Completion Date
December 31, 2025
Study Completion Date
August 31, 2026
pre-operative abemaciclib
pre-operatively for 4.5 days; 200mg twice daily (9 total doses)
Device for Cerebral Fluid Dialysate Collection
post-resection or post-biopsy continuous intracerebral microdialysis sampling for 48-hours to assess CNS drug entry and targeted inhibition with abemaciclib
Ashion Analytics GEM ExTra
resection/biopsy genomic sampling of tumor tissue and blood to identify therapeutic targets
abemaciclib + temozolomide
abemaciclib 150mg po BID and temozolomide 200mg/m2 po daily x 5 days in 28 day cycles (temozolomide 150mg/m2 po daily x 5 days for cycle 1)
RECRUITING
National Institutes of Health Clinical Center, Bethesda
National Cancer Institute (NCI)
NIH